InvestSMART

Vectus Biosystems Limited (ASX:VBS)

ALERT: Price-sensitive ASX Announcement for VBS
Current share price for VBS : $0.150 0.03 (25%)+
Announcement
Release
30 Apr 2026 3:10PM
Price at Release
$0.120
Full Release
download
Summary
Vectus Biosystems Limited, an Australian company, is developing treatments for fibrosis with a focus on heart, kidney, and liver diseases. Their lead compound, VB0004, aims to treat fibrosis and high blood pressure and has shown promising results in pre-clinical trials. During the March 2026 quarter, Vectus completed the sale of its VB4-P5 compound to XORTX Therapeutics Inc., receiving equity in return. The company has significantly reduced operating costs and is pursuing licensing opportunities. Cash used in operations was $236,000, with a cash balance of $94,000 at the quarter's end. Vectus has a loan facility with Director Maurie Stang, providing some financial flexibility. The company remains focused on commercializing its drug portfolio and expects to continue operations with reduced overheads and potential licensing revenue.
Key Points
  • Vectus Biosystems Limited focuses on developing treatments for fibrosis, targeting heart, kidney, and liver diseases.
  • VB0004 is the lead compound developed by Vectus to treat fibrosis and high blood pressure, having undergone successful pre-clinical trials.
  • Vectus finalized the sale of its VB4-P5 compound to XORTX Therapeutics Inc., receiving equity in XORTX as consideration.
  • The company reduced its operating costs and is exploring licensing opportunities and collaborations.
  • Net cash used in operating activities for the March 2026 quarter was $236,000, with a cash balance of $94,000 at the end of the period.
  • Vectus has a loan facility of up to $550,000 with Director Maurie Stang, with $450,000 drawn down.
  • The company expects to continue operations based on reduced overheads and licensing opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.